MOUNTAIN VIEW, Calif., Jan. 13, 2025 — Fenwick, a leading law firm renowned for its expertise in guiding technology and life sciences companies at every stage of growth, has entered into a strategic collaboration with Aumni (www.aumni.fund), a J.P. Morgan company specializing in venture capital data solutions, to deliver data-based market insights to the venture capital industry.

Starting in 2025, Fenwick and Aumni will jointly produce the quarterly Venture Beacon Report, among other data-driven insights throughout the year. By combining Aumni’s market-leading insights from a broad range of aggregated and anonymized transactions, with Fenwick’s deep legal and business expertise, this collaboration will empower clients and the broader start-up and venture community with actionable analyses in a rapidly changing landscape.

Fenwick has also adopted Aumni for seamless access to structured deal intelligence. Aumni’s data solutions give Fenwick the ability to extract and analyze critical legal and economic terms from its client’s venture financing deals, dramatically enhancing Fenwick’s data accessibility, analytical capabilities, and workflow efficiency.

“This collaboration marks an important evolution in venture market data reporting by addressing market trends with Fenwick and Aumni’s unique data and insights,” said Michael Sears, Managing Director at J.P. Morgan, and Head of Sales and Client Success at Aumni.

“Fenwick has built our reputation by helping innovative companies and investors tackle complex challenges and seize opportunities. Partnering with Aumni underscores our commitment to equipping clients with the data-based insights they need to stay ahead in a competitive and fast-moving venture ecosystem,” said Ian Goldstein, Fenwick partner and co-lead of its Startup & Venture Capital Practice.

About Fenwick: Fenwick is a leading law firm, purpose-built to guide visionary tech and life sciences companies and their investors through every stage of growth, from startups securing their first round of funding to leading publicly traded global enterprises. As one of Silicon Valley’s original legal practices, today we have over 500 lawyers, patent agents, engineers, and scientists serving clients all over the world. We are consistently ranked a Chambers first-tier firm for delivering the deep experience and technical skill that help innovators at the forefront of their industries shatter boundaries and redefine what’s possible. Visit www.fenwick.com to learn more.

About Aumni: Aumni, a J.P. Morgan company, is a leading provider of venture capital data and portfolio solutions. Venture firms, limited partners, fund administrators, and law firms use Aumni’s features to collect, structure, monitor, analyze, report on, and manage portfolio company documents and data – allowing clients to track KPI performance, summarize LPA terms, conduct scenario modeling, analyze market insights for benchmarking, and more. Aumni was founded in 2018 and acquired by J.P. Morgan in 2023. For more information, please visit www.aumni.fund.

SOURCE Fenwick

SAN FRANCISCO, Jan. 13, 2025 — Kerna Laboratories Inc, a San Francisco-based AI biotech startup, emerged from stealth with the launch of an AI platform for developing novel RNA-based medicines. By tackling critical mRNA design and delivery challenges, the company aims to unlock the full potential of mRNA as a universal toolkit for genetic medicine.

Founded nine months ago by biotech industry veterans Amit Deshwar (ex-SVP, Deep Genomics), Melissa J. Moore (ex-CSO, Moderna), Julia Peng (CEO), and Michael Swift (Founding Scientist), Kerna Labs brings unmatched expertise in mRNA technology and AI-driven sequence design. “We are redefining how mRNA sequences are designed and delivered,” said Julia Peng. “By leveraging artificial intelligence, we’re able to address bottlenecks in payload design, unlocking mRNA’s immense potential to address previously untreatable conditions.”

Although mRNA has seen groundbreaking success in recent years, significant challenges in payload design and delivery have restricted its use beyond infectious disease. Kerna Labs tackles these limitations with next-generation foundation models of RNA. “Foundation models of biology are allowing us to optimize mRNA in ways that weren’t conceivable just a few years ago,” said Amit Deshwar.

Kerna Labs recently closed an oversubscribed seed funding round, with investors including Gradient, Humba Ventures, Tau Ventures, Pioneer Fund, Focalpoint Partners, and prominent angels including Patrick Hsu (Arc Institute) and Jacob Kimmel (NewLimit). “Kerna Labs has taken an innovative approach to mRNA design and development,” said Darian Shirazi, Managing Partner at Gradient. “We’re excited to partner with a team that combines frontier AI and deep biotech expertise to transform the mRNA design and development landscape.”

With a mission to expand mRNA’s therapeutic possibilities, Kerna Labs is pushing the boundaries of what’s possible in genetic medicine. “We’re on the cusp of a major leap forward in genetic medicine, and Kerna Labs is at the forefront of making that vision a reality by harnessing the power of AI applied to mRNA,” said Melissa J. Moore.

About Kerna Laboratories Inc.
Kerna Laboratories Inc. is a San Francisco-based AI biotechnology company dedicated to unlocking the full potential of mRNA. Founded by leading experts, the company combines advanced AI and cutting-edge science to overcome mRNA payload design and delivery bottlenecks, paving the way for a new generation of therapies.

For collaboration inquiries, please contact [email protected].

Contact
Julia Peng
[email protected] 

SOURCE Kerna Laboratories, Inc

SHENZHEN, China, Jan. 13, 2025 — Addentax Group Corp. (“Addentax” or the “Company”) (Nasdaq: ATXG), an integrated service provider focusing on garment manufacturing, logistics services, property management, and subleasing, has announced that Addentax has purchased 3,750,000 common shares in Well Information Technology Corporation (“Well InfoTech”), a company incorporated under the jurisdiction of the State of Nevada. Well InfoTech and its subsidiaries are headquartered in Hangzhou, People’s Republic of China.

Well InfoTech’s core expertise lies in providing a comprehensive range of marketing solutions, including both online and offline marketing plans. Well InfoTech mainly serves store owners and managing personnel in fresh food industry across People’s Republic of China, mainly targeting large cities in China, such as Hangzhou, Beijing, and Heilongjiang. Their mission is to deliver comprehensive and tailored marketing solutions that enhance the visibility and profitability of fresh food store owners. Well InfoTech is committed to leveraging the latest digital tools and traditional marketing techniques to connect businesses with their customers, build lasting relationships, and promote a culture of healthy eating.

Pursuant to the Securities Purchase Agreement, the Company acquired 2.5% equity stake in Well InfoTech for a total consideration of USD $750,000. The investment was made in cash.

About Addentax Group Corp.

Addentax Group Corp. is an integrated service provider specializing in garment manufacturing, logistics services, and property management and subleasing. For more information about the Company, please visit the website: https://www.addentax.com/.

Caution Concerning Forward Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements in nature within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, the Company’s and Well InfoTech’s expectations with respect to the Agreement, the valuation of Well InfoTech including the products it offers and the markets in which it operates, and the Company and Well InfoTech’s projected future results, and known and unknown risks and uncertainties which are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions are intended to identify such forward-looking statements. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to consider risk factors, including those described in the Company’s filings with the U.S. Securities and Exchange Commission, that may affect the Company’s future results. All forward-looking statements attributable to the Company and its subsidiaries or persons acting on their behalf are expressly qualified in their entirety by these risk factors. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. These forward-looking statements are based on information currently available to Addentax and its current plans or expectations and are subject to a number of known and unknown uncertainties, risks and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to (i) risks related to the purchase of shares of Well InfoTech’s common stock, including risks related to the Company’s ability to realize some or all of the anticipated benefits from the purchase of the shares of Well InfoTech’s common stock, and (ii) other risks as set forth from time to time in the Company’s filings with the U.S. Securities and Exchange Commission, including the factors described in detail in the “Risk Factors” section of Addentax’s Annual Report on Form 10-K for the year ended March 31, 2024. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur, except as may be required by law.

Company Contact:

Public Relations Contact:
Addentax Group Corp.
Phone: + (86) 755 86961 405
[email protected] 

Investor Relations Contact:

Sherry Zheng
Weitian Group LLC
1-718-213-7386
[email protected] 

SOURCE Addentax Group Corp.

The funding will support Fermata’s mission of transforming horticultural data into real intelligence. Fermata’s suite of interconnected tools, each designed to address specific challenges faced by farmers, leverages diverse data sources and AI-driven insights to help growers make informed decisions

TEL AVIV, Israel, Jan. 13, 2025 — Fermata, a data science company specializing in computer vision agriculture solutions, closes $10 million in a Series A funding round backed by Raw Ventures. This investment will support the company’s strategic vision of developing a centralized digital brain for the horticulture industry, allowing autonomous management of crops through advanced data analysis, creating an ever-evolving system that continuously learns from available data.

The agricultural industry is characterized by a dual challenge: on the one hand, much of it remains predominantly non-digital, with farmers relying on intuition and experience to identify and diagnose crop issues—an approach that is often time-consuming and imprecise. On the other hand, even in advanced greenhouses where tech solutions are implemented, the sheer volume of data generated can overwhelm growers, leaving them unable to extract meaningful insights. As a result, many continue to rely on traditional methods, rather than utilizing the potential of the data to make informed, actionable decisions.

Initially focusing on identifying pests and diseases, the funding will be used to expand Fermata’s system into a command center for crop health, further developing its suite of AI-driven solutions to address a range of agricultural challenges. Using advanced data analytics, the system monitors a wide range of plant health factors, from fertilization to pollination status, with future capabilities set to include forecasting tools like yield prediction tracking. Fermata’s Croptimus suite will process visuals collected through its products, and integrate third-party data sources to build more accurate models.

If a grower is already using solutions for data collection, this information could be integrated with Fermata’s products in the future to generate advanced predictive insights. For growers not yet collecting data, cameras can be installed to monitor plant health. As visual data is gathered—whether from sensors or other sources—Fermata continuously uses it to refine and improve the accuracy of its insights and predictions. The company has already forged strategic collaborations with Microsoft, NVIDIA, Wageningen University, Bayer Crop Sciences, yieldsApp, and agRE.tech, and plans to continue partnering with industry leaders to expand its impact throughout the agritech sector.

These new capabilities build on Fermata’s current offerings, as its Croptimus suite provides 24/7 crop monitoring through computer vision to ensure plants remain healthy while scouting for potential threats. This approach has already demonstrated the potential to generate 30 percent savings on lost crops, while minimizing the need to use harmful pesticides. Fermata’s proprietary data allows them to build models that are not only accurate and highly efficient but also cost-effective to run, further enhancing the scalability of their solutions.

“Over the past five years, Fermata has been on a journey to discover the best applications of computer vision to meet growers’ needs,” says Valeria Kogan, Founder and CEO of Fermata. “We proudly call what we’ve built, ‘The Eyes of Ag.’ With the new funding, I’m thrilled to see Fermata scaling to bring all the other senses to the agricultural industry, ultimately evolving into its Brain. I’m happy we are a part of a global collaborative effort to shape the farming of tomorrow.”

“Raw Ventures is proud to continue supporting Fermata, reaffirming our commitment to driving investments in sustainability,” says Victoria Palatnik, managing partner of Raw Ventures. “As always, our support goes far beyond funding, providing substantial resources to help the company succeed. This latest funding round highlights Fermata’s impressive achievements, including significant technological milestones, the development of impactful partnerships, and a transformative effort by its management team, which has guided the company from an early-stage startup toward becoming a resilient and mature business.”

About Fermata

Fermata is focused on the application of data science and computer vision solutions to challenges faced by commercial agriculture. Engaged in extensive research since the company’s founding in 2020, Fermata has now developed an adaptive computer vision platform designed to automatically detect pests and diseases at their earliest stages. This early-detection platform, known as Croptimus™, enables growers to reliably mitigate these issues in advance of the point crop loss becomes inevitable and further reduces the amount of time and money spent on traditional scouting. For more information, visit: https://www.fermata.tech.

Media Contact:
Inbar Kneller
ReBlonde for Fermata
[email protected] 

SOURCE Fermata

SAN JOSE, Calif., Jan. 13, 2025 — Startup World Cup, #1 startup pitch competition in the world, successfully hosted its first Startup World Cup CES Las Vegas Regional competition on January 9, 2025.

SolCold impressed the judges with its groundbreaking cooling coating technology, a unique off-grid solution that requires no energy input. This innovative product transforms heat into cooling, reducing emissions and energy consumption—making it ideal for sun-exposed outdoor applications across various industries.

As the regional winner, SolCold advances to the Startup World Cup Grand Finale, to be held in San Francisco on October 17, 2025, where they will compete for the ultimate prize: a $1,000,000 investment.

The event was organized by Pegasus Tech Ventures, a Silicon Valley-based global venture capital firm, was judged by a distinguished panel of investors, who selected SolCold as the winner based on its innovation and market potential.

Judging Panel:

1. Jay Eum, GFT Ventures
2. Aidan Madigan-Curtis, Eclipse Ventures
3. Hanho Lee, Investment Director, Samsung Ventures
4. Deborah Magid, DoubleStar Venture Partners
5. Jeff Saling, Fund NV

“We were thrilled to bring Startup World Cup to CES Las Vegas this year,” said Anis Uzzaman, Founder and CEO of Pegasus Tech Ventures, who launched the competition in 2016. “The passion and innovation displayed by the 16 finalists were inspiring. I’m excited to see SolCold take the stage at our Grand Finale and showcase their vision to a global audience.”

Top 16 Finalists from CES Las Vegas Regional:

1. SolCold Ltd.
2. 3dnextech
3. Salva Health
4. E3A Healthcare Pte. Ltd.
5. Langcode Inc.
6. Bumpr
7. Perovskia Solar AG
8. MISSION SPACE
9. Atlas Magnetics
10. OursBlanc
11. Ampcera Inc.
12. Jmem Technology Co., Ltd.
13. AEOL KOREA
14. myFirst
15. StethoMe
16. Water Design Japan

About Startup World Cup
Startup World Cup is a global conference and competition designed to connect startup ecosystems worldwide. The competition offers startups the chance to compete for a $1,000,000 investment prize. In 2025, over 100 regional events will be held across North America, South America, Europe, Africa, and Asia, culminating in the Grand Finale in San Francisco on October 17, 2025.

Grand Finale Event Details:
Startup World Cup 2025 Grand Finale 
October 17, 2025 
San Francisco Hilton Union Square
Check out the Grand Finale video highlights.

About Pegasus Tech Ventures
Pegasus Tech Ventures is a global venture capital firm headquartered in Silicon Valley, managing over $2 billion in assets. Pegasus provides intellectual and financial capital to emerging technology companies and offers a unique Venture Capital-as-a-Service (VCaaS) model, partnering with global corporations to invest in cutting-edge startups. Corporate partners include SEGA, ASUS, AISIN, Niterra, and Sojitz, with access to an extensive portfolio of 270+ companies, including SpaceX, Airbnb, SoFi, Robinhood, and many more.

For more information, visit Startup World Cup and Pegasus Tech Ventures.

SOURCE Pegasus Tech Ventures

HUNTINGTON, N.Y., Jan. 13, 2025 — Sen-Jam Pharmaceutical is proud to announce a pivotal moment in its mission to transform the way the world heals by tackling inflammation at its source. With our groundbreaking PAIR (Pleiotropic Anti-Inflammatory Remedies) technology, we are developing novel therapeutics that address acute, chronic, and systemic inflammatory conditions across a wide spectrum of health challenges, including metabolic disorders, obesity, acute infections, and low-grade chronic inflammation associated with aging.

A Vision to Heal Upstream

Our proprietary PAIR technology is designed to address inflammation further upstream, reducing the cascade of damage before it begins. By targeting inflammation at its source through dual mechanisms of action, Sen-Jam’s approach preserves tissue integrity, protects healthspan, and supports the body’s innate healing capabilities. This pioneering strategy represents a paradigm shift in inflammatory care, paving the way for a future where vitality is preserved and disease progression is mitigated.

A Robust Pipeline of Breakthrough Therapeutics

Sen-Jam’s innovative pipeline is aimed at resolving diverse inflammatory conditions:

• SJP-002C: SJP-002C is a groundbreaking therapeutic for upper respiratory infections, including COVID-19, and has shown promising results in a recently completed Phase 2 clinical trial. Its ability to modulate inflammation at its source positions it as a disruptive force in the massive global upper respiratory market. Beyond addressing respiratory illnesses, SJP-002C’s anti-inflammatory properties offer significant potential in managing metabolic disorders linked to chronic inflammation, including obesity and Metabolic Associated Steatotic Liver Disease (MASLD), by mitigating the systemic inflammatory response that exacerbates these conditions.
• SJP-001: Currently in Phase 2 clinical trials in Australia, SJP-001 is a revolutionary solution targeting alcohol-induced inflammation (commonly known as hangover). By reducing inflammatory symptoms, it is poised to transform global workplace productivity and improve the quality of life for social drinkers. Additionally, SJP-001’s unique ability to resolve inflammation without suppressing the immune system positions it as a potential adjunct in managing metabolic disorders, offering relief to those whose metabolic health is impacted by chronic inflammation and food and drink overindulgence.
• SJP-100: SJP-100 is a first-in-class injectable designed to combat runaway inflammation in hospital settings, addressing acute care and life-threatening inflammatory conditions. Its precision-targeted approach provides a critical solution for patients in crisis, while its potential applications extend to severe metabolic dysfunctions where inflammation drives rapid health deterioration, such as advanced obesity-related complications and liver inflammation.ng a critical solution for acute care and life-threatening inflammatory conditions.
• SJP-005: SJP-005 is Sen-Jam’s non-opioid solution for opioid withdrawal, offering a revolutionary approach to combating the opioid crisis by reducing dependency and easing recovery. By modulating the inflammation associated with withdrawal symptoms, this therapeutic not only supports addiction recovery but also offers a pathway to better metabolic health for patients, as opioid use and withdrawal are often linked to metabolic dysregulation.
• Anti-Aging Innovation: Sen-Jam’s preemptive inflammation resolution technologies aim to combat low-grade chronic inflammation, a key contributor to aging and age-related diseases. This innovative platform holds immense promise for anti-aging therapeutics and for addressing metabolic disorders, including obesity and insulin resistance, by targeting the root causes of systemic inflammation that undermine vitality and longevity.

Transforming Healthcare Through Innovation

“Sen-Jam is not just developing therapies; we’re rewriting the playbook on how we approach inflammation and healing,” said Neal Zahn, Director of Global Licensing. “By addressing inflammation upstream, we’re creating solutions that preserve healthspan and empower the body’s natural defenses to thrive. This is the future of medicine.“

Jackie Iversen RPh MS, Co-Founder and Chief Clinical Officer, adds, “Our pipeline represents more than just innovation—it’s a commitment to challenging the status quo and delivering real, lasting impact for patients worldwide.”

Join Us in San Francisco

Sen-Jam’s leadership team is in San Francisco this week for the prestigious JPMorgan Healthcare Conference. We invite interested parties to reach out to learn more about our vision, pipeline, and partnership opportunities. Let’s connect and shape the future of healthcare together. To learn more visit wefunder.com/senjam. 

About Sen-Jam Pharmaceutical

Sen-Jam Pharmaceutical: Revolutionizing Inflammatory and Metabolic Care

Sen-Jam Pharmaceutical (“Sen-Jam”) is pioneering a revolutionary approach to addressing chronic inflammation and metabolic disorders, including obesity, with our proprietary “Pleiotropic Anti-Inflammatory Remedies” (or “PAIR”) technology. By working in harmony with the body’s innate immune system, our precision remedies target inflammation at its source, mitigating systemic risks associated with chronic conditions without suppressing the immune response. Sen-Jam is at the forefront of the next evolution in healthcare, delivering innovative treatments that enhance metabolic health, promote vitality, extend health spans, and redefine how the world heals.

CONTACT INFORMATION:
Sen-Jam Pharmaceutical
Christine Leonard
[email protected]
781-913-1902

SOURCE Sen-Jam Pharmaceutical

While technology has become part of almost any classroom, a majority of teachers still prefer pen and paper as their go-to teaching tool. Studies show that handwriting is key to comprehension, knowledge retention, and creativity. Jotit brings “digital-paper” to the classroom, allowing students and teachers to enjoy the benefits of both digital and traditional methods.

Built with simplicity and functionality at its core, Jotit is already making a significant impact in schools across the United States. By reducing administrative burdens and enabling distraction-free learning, the platform is reshaping classroom dynamics. Features like advanced handwriting recognition, real-time collaboration tools, and customizable workflows are delivering measurable results among K-12 students.

David Bleicher, Jotit’s CEO and Co-Founder, highlighted the significance of the partnership and the company’s mission: “At Jotit, we aim to empower educators and students by fostering a distraction-free learning environment where handwriting takes center stage. The tremendous support from Owl Ventures and our esteemed investors is a powerful endorsement of our vision. Together, we’ll expand our reach and empower more educators to leverage technology to improve learning and drive better results.”

“Jotit’s approach to technology in the classroom is different; We introduce it only where it reinforces proven educational value: Order, executive-function and active learning”

“We’ve been envisioning and searching for a product like Jotit that brings back the joy of writing into the classroom. Jotit’s innovative and seamless learning platform is clearly resonating with teachers and students, and the company is poised to establish itself as one of the most trusted brands within K-12 classrooms,” said Jenny Wang, Partner at Owl Ventures. “We are excited to partner with the Jotit team and help scale this transformative platform to K-12 schools across the US and around the globe.”

With the enthusiastic backing of its new partners and investors, Jotit is redefining the use of technology in schools.

About Jotit

Jotit is an innovative ed-tech company transforming how students, teachers, and parents stay organized with handwriting-focused tools. By combining cutting-edge technology with intuitive simplicity, Jotit fosters focused, engaging, and effective learning. Jotit is available in K-12 schools across the US. [Jotit]

About Owl Ventures

Owl Ventures is the largest venture capital firm in the world focused on the education technology market. With over $2 billion in assets under management, Owl Ventures invests in the world’s leading education technology companies across the education spectrum encompassing early childhood, K-12, higher education, and career mobility/professional learning. The firm has deep domain expertise and leverages a global network of Limited Partners, investors, and strategic partners to help entrepreneurs scale their businesses into transformative category-leading companies. [Owl Ventures]

For media inquiries, please contact: [email protected]

Photo – https://mma.prnewswire.com/media/2593754/Jotit_Classroom.jpg

SOURCE Jotit

Company reports 300% revenue growth in 2024 and advances partnerships with nation’s leading health systems

LOUISVILLE, Ky., Jan. 10, 2025 — RAAPID, the industry-leading healthcare AI company, announced today a significant Series A investment from M12, Microsoft’s venture fund. This strategic funding positions RAAPID to expand its groundbreaking Neuro-symbolic AI platform that is reshaping healthcare risk adjustment.

RAAPID’s explosive growth – marked by a 300% revenue increase in 2024 – demonstrates the market’s strong validation of its advanced technology platform. The company has quickly established itself as a trusted partner for major health plans and provider., At the core of RAAPID’s success is its pioneering VisionAI technology, which tackles one of healthcare’s most pressing challenges: making sense of unstructured medical data. While over 70% of medical records exist as unstructured data when shared outside EHRs, RAAPID’s AI engine transforms this complex information into actionable insights, enabling unprecedented accuracy in risk capture and care gap identification.

“Our vision extends beyond traditional risk adjustment,” states Chetan Parikh, Founder and CEO of RAAPID. “We’re creating a future where AI augments healthcare professionals’ capabilities, leading to better patient outcomes and more accurate appropriate reimbursements. This investment from M12 accelerates our mission to transform healthcare through advanced AI.”

RAAPID’s purpose-built Risk Adjustment platform has achieved remarkable results:

• Slashing chart review time by 60-80%
• Surpassing industry standards with 95%+ coding accuracy
• Generating additional appropriate and compliant revenue per member
• Improving risk capture accuracy by 25%

The HITRUST-certified platform stands out for its unique Neuro-symbolic AI approach, combining neural networks with an extensive medical knowledge graph containing over 4 million clinical entities and 50 million relationships. This sophisticated technology enables both retrospective analysis and prospective risk adjustment, helping organizations identify and address care gaps to positively impact patient health.

“Healthcare organizations are increasingly seeking innovative solutions to manage risk and improve care delivery in value-based arrangements,” said Todd Graham, Managing Partner at M12. “RAAPID’s AI-driven risk adjustment platform aligns perfectly with our investment strategy. Through M12, we are committed to providing our portfolio companies with access to Microsoft’s resources and expertise to drive significant impact in the healthcare sector.

Led by a team with over 25 years of healthcare technology expertise, RAAPID has collaborated with experts from the top 4 tech giants in developing its clinical AI solutions. RAAPID continues to push the safe boundaries of what’s possible in healthcare AI. The company’s selection as an M12 portfolio company validates its position as a leader in healthcare technology innovation.

As value-based care becomes increasingly important, RAAPID’s AI-powered solutions are becoming essential tools for healthcare organizations striving to improve timeliness and quality of care all patients expect. With this new funding, RAAPID is poised to further advance its technology and expand its positive impact on patients, providers and payers.

About RAAPID
RAAPID develops AI-powered solutions for healthcare payers, providers, and supporting organizations. The company’s cloud-based risk adjustment platform uses neuro-symbolic AI to identify chronic conditions, determine HCC codes, calculate risk scores, and analyze population health trends. RAAPID serves organizations that participate in Medicare Advantage, ACA, Medicare ACO, and Medicaid programs.

For more information about RAAPID’s AI-powered risk adjustment solutions, visit www.raapidinc.com

CONTACT:
Mayur Vyas
(502) 699-3044
[email protected]

SOURCE RAAPID

• High unmet medical need for therapies that can reduce the substantial treatment burden affecting millions of patients globally
• Combined in-licensing and financing for a novel long-acting clinical stage monoclonal antibody targeting TSLP ligand as well as building a discovery pipeline of long-acting bispecifics
• Naveed Siddiqi, Senior Partner, Venture Investments, Novo Holdings, to join the Windward Bio Board of Directors

COPENHAGEN, Denmark, Jan. 10, 2025 — Novo Holdings, a leading life science investor, today announced that it has invested in a $200M Series A launch financing for Windward Bio. Headquartered in Switzerland, Windward Bio is a clinical-stage drug development company committed to improving outcomes for people living with advanced immunological diseases with an initial focus on severe respiratory conditions.

The oversubscribed Series A launch financing was co-led by OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities, and joined by SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners.

Windward Bio’s lead candidate, WIN378, which has been in-licensed from Kelun-Biotech and Harbour BioMed, is a potential best-in-class, long-acting monoclonal antibody targeting the ligand of thymic stromal lymphopoietin (TSLP) that has the potential to be dosed every six months.

The Company is preparing to begin a Phase 2 trial investigating WIN378 in severe asthma, with initial clinical readouts expected in 2026. Additional clinical trials are planned in asthma and chronic obstructive pulmonary disease (COPD), aiming to address unmet needs in approximately 5 million advanced, uncontrolled patients in the US, Europe, and Japan.

In addition to WIN378, Windward Bio is building a discovery pipeline of long-acting bispecifics, harnessing validated targets and synergistic biology to achieve best-in-disease efficacy for immunology indications. The Series A financing supports the advancement of two undisclosed programs through Investigational New Drug (IND)–enabling studies.

“Our mission in starting Windward Bio is to discover and develop novel therapeutics for people living with serious immunological conditions,” said Luca Santarelli, MD, founder, CEO, and Chairman of Windward Bio. “Targeting the TSLP ligand is a highly validated approach in multiple immunological conditions, and WIN378 represents a significant advance in TSLP therapy by enhancing the benefits of this class with a dosing regimen of every six months, which can reduce the burden of treatment and improve outcomes for people living with severe asthma.”

Naveed Siddiqi, Senior Partner, Novo Holdings, said: “Addressing the unmet needs of patients with severe, uncontrolled asthma and COPD, particularly through innovative therapies that reduce the burden of care for both individuals and healthcare systems, represents a meaningful advancement in respiratory care. WIN378, with its best-in-class potential to provide effective treatment through a six-month dosing regimen, could transform how these challenging conditions are managed, offering both clinical and practical benefits. At Novo Holdings, we are committed to supporting innovative approaches that improve patient outcomes. We are excited to partner once again with the management team of Windward Bio, serial entrepreneurs with a proven track record of success.”

Led by CEO Luca Santarelli, Windward Bio’s founding team comprises seasoned biopharmaceutical executives with significant expertise in advancing compounds from target identification through to commercialisation. Collectively, they have contributed to over 15 product launches, executed two Nasdaq IPOs, and completed two strategic exits.

The Board of directors will initially include Luca Santarelli, MD (CEO); David Bonita, MD (OrbiMed); Naveed Siddiqi, MD (Novo Holdings); Tim Anderson (Blue Owl Healthcare Opportunities); Iqbal Mufti (SR One); and Otello Stampacchia, PhD (Omega Funds). Campbell Stewart, MD (Principal, Venture Investments, Novo Holdings), joins as Observer to the Board.

About WIN378

WIN378 is a novel, recombinant, fully human monoclonal antibody that potently binds to the TSLP ligand, which is a well-validated cytokine that plays a key role in the development and progression of a wide array of immunological diseases, including asthma and COPD. In both these diseases the inhibition of the TSLP ligand has demonstrated benefit in a myriad of inflammatory phenotypes. WIN378 has been engineered to achieve an extended half-life and effector silencing and is subcutaneously administered.

About Windward Bio AG

Windward Bio is a clinical-stage drug development company committed to improving outcomes for patients living with advanced immunological diseases with an initial focus on severe respiratory conditions. The company is led by a highly experienced team of biopharmaceutical executives with deep discovery, development, and commercialization expertise. The company is advancing a potential best-in-class TSLP monoclonal antibody into phase 2 development and creating novel, long-acting bispecific programs for immunological diseases.

About Novo Holdings A/S

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2023, Novo Holdings had total assets of EUR 149 billion. www.novoholdings.dk

About the Novo Nordisk Foundation

Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people’s health and the sustainability of society and the planet. The Foundation’s mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society.

SOURCE Novo Holdings